IBRANCE® (palbociclib) receives FDA regular approval and expanded indication for first-line HR+, HER2- metastatic breast cancer

3rd April 2017 Uncategorised 0

Pfizer

More: IBRANCE® (palbociclib) receives FDA regular approval and expanded indication for first-line HR+, HER2- metastatic breast cancer
Source: MDlinx